Molecule of the month. The 'skinny' on CB1 antagonists/inverse agonists: controversial obesity drugs will not go to FDA for approval.
Lindsley
Craig W
CW
Vanderbilt University, Vanderbilt University Medical Center, Department of Pharmacology, Nashville, TN 37232-6600, USA.
D000818:Animals; D019440:Anti-Obesity Agents / Q000009:adverse effects* / Q000737:chemistry / Q000627:therapeutic use; D017277:Drug Approval; D054314:Drug Inverse Agonism; D006801:Humans; D009765:Obesity / Q000188:drug therapy*; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors* / Q000737:chemistry; D014481:United States; D014486:United States Food and Drug Administration
D019440:Anti-Obesity Agents; D043884:Receptor, Cannabinoid, CB1